SEC Form 4 · accession 0001209191-15-071277
Anacor Pharmaceuticals, Inc. · ANAC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul L Berns
Officer — President and CEO · Director
Period of report
Sep 15, 2015
Accepted (ET)
Sep 17, 2015 · 9:46 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411158
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 15, 2015 | M | 4,000 | $5.11 | A | 258,760 | D | |
| Common Stock | Sep 15, 2015 | M | 16,000 | $5.20 | A | 274,760 | D | |
| Common StockF2,F3 | Sep 15, 2015 | S | 1,992 | $139.0309 | D | 272,768 | D | |
| Common StockF2,F4 | Sep 15, 2015 | S | 16,209 | $139.8342 | D | 256,559 | D | |
| Common StockF2,F5 | Sep 15, 2015 | S | 1,799 | $140.6369 | D | 254,760 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F6 | $5.11 | Sep 15, 2015 | M | 4,000 | D | — | Jun 6, 2023 | Common Stock | 4,000 | 0 | D |
| Stock Option (right to buy)F6 | $5.20 | Sep 15, 2015 | M | 16,000 | D | — | May 30, 2022 | Common Stock | 16,000 | 14,000 | D |
Explanation of responses
- F1This sale was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person for tax and estate planning purposes.
- F2The price reported in Column 4 is a weighted average price.
- F3These shares were sold in multiple transactions at prices ranging from $138.334 to $139.28, inclusive.
- F4These shares were sold in multiple transactions at prices ranging from $139.42 to $140.40, inclusive.
- F5These shares were sold in multiple transactions at prices ranging from $140.43 to $140.91, inclusive.
- F6This option is fully vested and exercisable.